{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:17:48Z","timestamp":1792721868635,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00777-y","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T15:38:18Z","timestamp":1766763498000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Piani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios L.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"6","key":"777_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"777_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","volume":"26","author":"T Bardin","year":"2014","unstructured":"Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186\u201391.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"777_CR3","doi-asserted-by":"publisher","first-page":"103796","DOI":"10.1016\/j.numecd.2024.103796","volume":"35","author":"M Kuwabara","year":"2025","unstructured":"Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, Andres-Hernando A, et al. Hyperuricemia, A new cardiovascular risk. Nutr Metab Cardiovasc Dis. 2025;35(3):103796.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"777_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41440-023-01273-3","volume":"46","author":"M Kuwabara","year":"2023","unstructured":"Kuwabara M, Kodama T, Ae R, Kanbay M, Andres-Hernando A, Borghi C, et\u00a0al. Update in uric acid, hypertension, and cardiovascular diseases. Hypertens Res. 2023;46(7):1714\u201326.","journal-title":"Hypertens Res"},{"key":"777_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2018.03.077","volume":"261","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Kuwabara M, Johnson R, Bove M, Fogacci F, Rosticci M, Giovannini M, D\u2019Addato S, Borghi C, Brisighella Heart Study group. LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella heart study cohort. Int J Cardiol. 2018;261:204\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.077.","journal-title":"Int J Cardiol"},{"key":"777_CR6","doi-asserted-by":"crossref","unstructured":"Mengozzi A, Pugliese NR, Desideri G, Masi S, Angeli F, Barbagallo CM et al. Serum uric acid predicts All-Cause and cardiovascular mortality independently of hypertriglyceridemia in cardiometabolic patients without established CV disease: a sub-analysis of the uric acid right for heart health (URRAH) study. Metabolites. 2023;13(2).","DOI":"10.3390\/metabo13020244"},{"key":"777_CR7","first-page":"101453","volume":"54","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Lian Q, Nie Y, Zhao W. Causal relationship between serum uric acid and cardiovascular disease: a Mendelian randomization study. Int J Cardiol Heart Vasc. 2024;54:101453.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"777_CR8","first-page":"101503","volume":"54","author":"C Borghi","year":"2024","unstructured":"Borghi C, Fogacci F, Piani F. Causal relationship between serum uric acid and cardiovascular disease: a Mendelian randomization study. Int J Cardiol Heart Vasc. 2024;54:101503.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"7","key":"777_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00392-021-01815-0","volume":"110","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Mengozzi A, Virdis A, Casiglia E, Tikhonoff V, Cicero AFG, et al. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clin Res Cardiol. 2021;110(7):1073\u201382.","journal-title":"Clin Res Cardiol"},{"key":"777_CR10","doi-asserted-by":"publisher","unstructured":"Borghi C, Fogacci F, Cicero AF. Crystal clear - part I: The role of uric acid in cardiorenal disease. Eur J Intern Med. 2025 Jul 26:S0953-6205(25)00312-7. https:\/\/doi.org\/10.1016\/j.ejim.2025.07.028. Epub ahead of print.","DOI":"10.1016\/j.ejim.2025.07.028"},{"issue":"5","key":"777_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40292-023-00602-4","volume":"30","author":"A Maloberti","year":"2023","unstructured":"Maloberti A, Mengozzi A, Russo E, Cicero AFG, Angeli F, Agabiti Rosei E, et al. The results of the URRAH (Uric acid right for heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev. 2023;30(5):411\u201325.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"777_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"777_CR13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768\u201379.","journal-title":"Ann Rheum Dis"},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"o1754","DOI":"10.1136\/bmj.o1754","volume":"378","author":"J Neilson","year":"2022","unstructured":"Neilson J, Bonnon A, Dickson A, Roddy E. Gout: diagnosis and management-summary of NICE guidance. BMJ. 2022;378:o1754.","journal-title":"BMJ"},{"issue":"5","key":"777_CR15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s10147-016-0971-3","volume":"21","author":"K Tamura","year":"2016","unstructured":"Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, et al. Efficacy and safety of febuxostat for prevention of tumor Lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016;21(5):996\u20131003.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"777_CR16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","volume":"26","author":"M Spina","year":"2015","unstructured":"Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor Lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155\u201361.","journal-title":"Ann Oncol"},{"issue":"9","key":"777_CR17","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3899\/jrheum.110092","volume":"38","author":"S Chohan","year":"2011","unstructured":"Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957\u20139.","journal-title":"J Rheumatol"},{"issue":"12","key":"777_CR18","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","volume":"36","author":"BJ Paul","year":"2017","unstructured":"Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36(12):2637\u201344.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"777_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14656566.2015.985588","volume":"16","author":"MB Bridgeman","year":"2015","unstructured":"Bridgeman MB, Chavez B. Febuxostat for the treatment of gout. Expert Opin Pharmacother. 2015;16(3):395\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"777_CR20","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"11","key":"777_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr., Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540\u20138.","journal-title":"Arthritis Rheum"},{"issue":"13","key":"777_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"10264","key":"777_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745\u201357.","journal-title":"Lancet"},{"issue":"8","key":"777_CR24","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","volume":"77","author":"A Sezai","year":"2013","unstructured":"Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77(8):2043\u20139.","journal-title":"Circ J"},{"issue":"12","key":"777_CR25","doi-asserted-by":"publisher","first-page":"300060521106277","DOI":"10.1177\/03000605211062770","volume":"49","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yoshihisa A, Yokokawa T, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Tsuda A, Tsuda T, Ishibashi T, Konno I, Yamaguchi O, Machii H, Nozaki N, Niizeki T, Miyamoto T, Takeishi Y. Multicenter randomized trial investigators. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. 2021;49(12):3000605211062770. https:\/\/doi.org\/10.1177\/03000605211062770.","journal-title":"J Int Med Res"},{"issue":"2","key":"777_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00380-024-02448-9","volume":"40","author":"T Yokota","year":"2025","unstructured":"Yokota T, Kinugawa S, Fukushima A, Okumura T, Murohara T, Tsutsui H. Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study. Heart Vessels. 2025;40(2):111\u201322.","journal-title":"Heart Vessels"},{"key":"777_CR27","doi-asserted-by":"publisher","unstructured":"Borghi C, Fogacci F, Cicero AF. Crystal clear-part II: the role of uric acid in cardiorenal disease. Eur J Intern Med. 2025 Oct;18:106554. https:\/\/doi.org\/10.1016\/j.ejim.2025.106554. Epub ahead of print.","DOI":"10.1016\/j.ejim.2025.106554"},{"issue":"2","key":"777_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10067-020-05272-4","volume":"40","author":"M Fan","year":"2021","unstructured":"Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, et al. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol. 2021;40(2):683\u201392.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"777_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.semarthrit.2013.05.004","volume":"43","author":"LI Faruque","year":"2013","unstructured":"Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum. 2013;43(3):367\u201375.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"777_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40360-023-00723-5","volume":"24","author":"H Xie","year":"2023","unstructured":"Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2023;24(1):79.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"777_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/clc.23643","volume":"44","author":"L Gao","year":"2021","unstructured":"Gao L, Wang B, Pan Y, Lu Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clin Cardiol. 2021;44(7):907\u201316.","journal-title":"Clin Cardiol"},{"issue":"10","key":"777_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.numecd.2019.06.016","volume":"29","author":"CW Liu","year":"2019","unstructured":"Liu CW, Chang WC, Lee CC, Shau WY, Hsu FS, Wang ML, et al. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia-a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2019;29(10):1011\u201322.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"777_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12882-022-02850-3","volume":"23","author":"T Sapankaew","year":"2022","unstructured":"Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P, et al. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol. 2022;23(1):223.","journal-title":"BMC Nephrol"},{"issue":"29","key":"777_CR34","doi-asserted-by":"publisher","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","volume":"98","author":"TC Lin","year":"2019","unstructured":"Lin TC, Hung LY, Chen YC, Lo WC, Lin CH, Tam KW, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Med (Baltim). 2019;98(29):e16311.","journal-title":"Med (Baltim)"},{"issue":"1","key":"777_CR35","doi-asserted-by":"publisher","first-page":"2332956","DOI":"10.1080\/07853890.2024.2332956","volume":"56","author":"XH Yang","year":"2024","unstructured":"Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2024;56(1):2332956.","journal-title":"Ann Med"},{"issue":"2","key":"777_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.amjmed.2024.09.018","volume":"138","author":"MH Tsai","year":"2025","unstructured":"Tsai MH, Chen YY, Liou HH, Wang JT, Fang YW. Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: a Population-Based cohort study. Am J Med. 2025;138(2):236. \u2013 44.e13.","journal-title":"Am J Med"},{"key":"777_CR37","doi-asserted-by":"crossref","unstructured":"Saito Y, Tanaka A, Yoshida H, Nakashima H, Ban N, Matsuhisa M et al. Effects of Xanthine oxidase Inhibition by febuxostat on lipid profiles of patients with hyperuricemia: insights from randomized PRIZE study. Nutrients. 2024;16(14).","DOI":"10.3390\/nu16142324"},{"issue":"6","key":"777_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"777_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2021.11.076","volume":"349","author":"M Konishi","year":"2022","unstructured":"Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, et al. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol. 2022;349:127\u201333.","journal-title":"Int J Cardiol"}],"updated-by":[{"DOI":"10.1007\/s40292-026-00796-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000}}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00777-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:42:53Z","timestamp":1780119773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00777-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00777-y","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the funding information and conflict of interest have been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40292-026-00796-3","URL":"https:\/\/doi.org\/10.1007\/s40292-026-00796-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have been supported by an educational grant by Berlin-Chemie AG, with registered office in Glienicker Weg 125 12489 Berlin, Germany","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a review and does not contain any studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human participants or animals performed by the authors. All cited studies are properly referenced and comply with ethical standards as reported by their respective authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}